Hassan Y, Brewer J M, Alexander J, Jennings R
Department of Medical Microbiology, University of Sheffield Medical School, UK.
Vaccine. 1996 Dec;14(17-18):1581-9. doi: 10.1016/s0264-410x(96)00155-7.
The purpose of this study was to evaluate the immunogenicity of a herpes simplex virus type I (HSV-1) antigen preparation, obtained following zwitterionic detergent treatment of virus, and incorporation of the antigens into either immunostimulating complexes (ISCOMs) or non-ionic surfactant vesicles (NISV) delivery systems. Using Balb/c mice the ISCOM and NISV HSV-1 vaccines were assayed for their capacity to induce and enhance both the humoral and cellular immune responses, and to elicit protection against both homologous and heterologous virus challenge. The serum from animals vaccinated with either the NISV or the ISCOM HSV-1 antigen preparation, were found to contain high levels of total IgG and IgG1 and IgG2a subclass antibodies. In addition, both preparations were found to induce high neutralizing (NT) antibody levels following a two immunization protocol and to provide some protection against homologous and heterologous HSV challenge infection. Lymphoproliferative responses were observed in cultures of splenocytes from mice immunized with both HSV-1 NISV vaccine and HSV-1 ISCOMs vaccine, following various antigenic stimuli in vitro. In general, these were most marked in animals immunized with the HSV-1 NISV preparation, and particularly so when the splenocytes were stimulated in vitro with live HSV-1. Both the NISV and ISCOM HSV-1 vaccines were found to have induced interleukin 2, interleukin 10 and interferon-gamma in spleen cell culture supernatants, although again, the highest responses in general were observed in supernatant fluids from spleen cell cultures from animals immunized with the HSV-1 NISV preparation. These results suggest that a wide range of immune activity can be elicited by HSV-1 antigens presented to the immune system of mice in these formulations.
本研究的目的是评估一种单纯疱疹病毒I型（HSV-1）抗原制剂的免疫原性，该制剂是在对病毒进行两性离子去污剂处理后获得的，并将抗原掺入免疫刺激复合物（ISCOMs）或非离子表面活性剂囊泡（NISV）递送系统中。使用Balb/c小鼠对ISCOM和NISV HSV-1疫苗进行检测，以评估它们诱导和增强体液免疫和细胞免疫反应的能力，以及引发针对同源和异源病毒攻击的保护作用。发现用NISV或ISCOM HSV-1抗原制剂接种疫苗的动物血清中含有高水平的总IgG、IgG1和IgG2a亚类抗体。此外，两种制剂在两次免疫方案后均能诱导产生高中和（NT）抗体水平，并对同源和异源HSV攻击感染提供一定保护。在用HSV-1 NISV疫苗和HSV-1 ISCOMs疫苗免疫的小鼠脾细胞培养物中，在体外进行各种抗原刺激后观察到淋巴细胞增殖反应。一般来说，在用HSV-1 NISV制剂免疫的动物中这些反应最为明显，尤其是当脾细胞在体外受到活HSV-1刺激时。发现NISV和ISCOM HSV-1疫苗均能在脾细胞培养上清液中诱导白细胞介素2、白细胞介素10和干扰素-γ，不过同样，一般在来自用HSV-1 NISV制剂免疫的动物的脾细胞培养物的上清液中观察到最高反应。这些结果表明，以这些制剂形式呈现给小鼠免疫系统的HSV-1抗原可引发广泛的免疫活性。
